Paul Perreault was appointed Chief Executive Officer (CEO) and Managing Director of CSL Limited in July 2013. Since then, CSL has grown to become the fifth largest biotechnology company in the world with more than 25,000 employees bringing lifesaving medicines to people in more than 60 countries.
Paul, who brings more than 30 years of experience in the global healthcare industry, joined CSL in 2004 when CSL Limited acquired Aventis Behring. Prior to his current role, Paul served as CSL Behring’s President and Executive Vice President of Worldwide Commercial Operations and Business Development. He also held several executive positions at Aventis Behring, including, Vice President and General Manager of Plasma Operations and Vice President and General Manager Hospital Products in North America and Puerto Rico.
In 2019, Paul was recognized as one of Harvard Business Review’s best-performing chief executives in the world as part of the business publication’s CEO 100 List. The annual ranking measures leaders across industries on financial performance as well as environmental, social, and governance criteria. In 2018, Paul was named one of the Philadelphia Business Journal’s Most Admired CEOs and “Humanitarian Man of the Year” by the Hemophilia Association of New Jersey. Additionally, the influential Australian Financial Review named Paul its 2017 CEO of the Year and, in 2016, Paul was awarded Healthcare CEO of the Year from the Philadelphia Alliance for Capital and Technologies.
Paul is also a member of the Wall Street Journal’s CEO Council and an inaugural member of the Penn State Provost’s Global Advisory Council. He also served on the board of Bunker Labs Philadelphia, a network of military veteran entrepreneurs.
Prior to CSL, Paul spent more than 15 years in key senior roles at Wyeth-Ayerst Laboratories, now a part of Pfizer.
Paul holds a bachelor’s degree in psychology from the University of Central Florida and completed advanced business management training at the Kellogg and Wharton schools of business.